Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
As control cells, BHK cell lines overexpressing IR-A or IGF1R alone were included
Tirzepatide: The Dual-Action GLP-1 and GIP Agonist Alternative Tirzepatide activates both GLP-1 and GIP receptorsa dual mechanism that some patients find more effective than GLP-1-only therapies
Three-year follow-up data showed that this weight loss was largely sustained over the longer term
The FDA granted accelerated approval in August 2025 for a new GLP-1-related indication, and the 2026 American Diabetes Association Standards of Care now recommend GLP-1 receptor agonists as preferred agents for specific patient groups
US$ 28.20
US$ 24.41
US$ 23.44
US$ 20.41
US$ 21.09
US$ 26.56
